The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

[1]  Michael P. Morrissey,et al.  Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features , 2018, Nature Communications.

[2]  S. Sleijfer,et al.  Pan-cancer whole genome analyses of metastatic solid tumors , 2018, bioRxiv.

[3]  Matthew D. Hellmann,et al.  Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 , 2018, Clinical Trials.

[4]  P. V. van Diest,et al.  Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. , 2018, Cancer research.

[5]  M. Stratton,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[6]  Mi Ni Huang,et al.  In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors , 2017, bioRxiv.

[7]  David Haussler,et al.  The UCSC Genome Browser database: 2018 update , 2017, Nucleic Acids Res..

[8]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[9]  Chuang Tan,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[10]  Edwin Cuppen,et al.  MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2016, Genome Medicine.

[11]  P. Lønning,et al.  Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.

[12]  Robert J. Lonigro,et al.  Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.

[13]  Sandro Morganella,et al.  Mutational Signatures in Breast Cancer: The Problem at the DNA Level , 2017, Clinical Cancer Research.

[14]  Bernat Gel,et al.  karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data , 2017, bioRxiv.

[15]  Michael P. Schroeder,et al.  Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.

[16]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[17]  Lajos Pusztai,et al.  Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.

[18]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[19]  A. Viale,et al.  Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.

[20]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[21]  Steven J. M. Jones,et al.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[22]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[23]  C. Lefebvre,et al.  Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.

[24]  Stephen Fox,et al.  The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE” , 2016, PLoS medicine.

[25]  C. Sotiriou,et al.  Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  E. Birney,et al.  Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration , 2016, Nature Communications.

[27]  E. Birney,et al.  The topography of mutational processes in breast cancer genomes , 2016, Nature Communications.

[28]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[29]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[30]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[31]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[32]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[33]  B. Teh,et al.  MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations , 2015, Scientific Reports.

[34]  C. Swanton,et al.  APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.

[35]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[36]  N. A. Temiz,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[37]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[38]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[39]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[40]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[41]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[42]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[43]  Renaud Gaujoux,et al.  A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.

[44]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[45]  M. Wyatt,et al.  Participation of DNA repair in the response to 5-fluorouracil , 2009, Cellular and Molecular Life Sciences.

[46]  Michael Hahsler,et al.  Getting Things in Order: An Introduction to the R Package seriation , 2008 .

[47]  Wolfgang Huber,et al.  Transcript mapping with high-density oligonucleotide tiling arrays , 2006, Bioinform..

[48]  E. L. Lehmann,et al.  Nonparametric Confidence Intervals for a Shift Parameter , 1963 .

[49]  J. L. Hodges,et al.  Estimates of Location Based on Rank Tests , 1963 .